Anhui Huaheng Biotechnology Co. Ltd. A
Anhui Huaheng Biotechnology Co., Ltd. engages in the research and development, production, and sale of bio-based products through bio-manufacturing in China and internationally. The company offers amino acid products, including the alanine series, L-valine, isoleucine, tryptophan, and arginine; vitamin products, such as D-pantothenate calcium, D-panthenol, and inositol; bio-based new material mon… Read more
Anhui Huaheng Biotechnology Co. Ltd. A (688639) - Net Assets
Latest net assets as of September 2025: CN¥2.67 Billion CNY
Based on the latest financial reports, Anhui Huaheng Biotechnology Co. Ltd. A (688639) has net assets worth CN¥2.67 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.67 Billion) and total liabilities (CN¥3.00 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.67 Billion |
| % of Total Assets | 47.04% |
| Annual Growth Rate | 62.05% |
| 5-Year Change | 422.35% |
| 10-Year Change | 2135.13% |
| Growth Volatility | 55.28 |
Anhui Huaheng Biotechnology Co. Ltd. A - Net Assets Trend (2012–2024)
This chart illustrates how Anhui Huaheng Biotechnology Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Anhui Huaheng Biotechnology Co. Ltd. A (2012–2024)
The table below shows the annual net assets of Anhui Huaheng Biotechnology Co. Ltd. A from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.56 Billion | +40.13% |
| 2023-12-31 | CN¥1.83 Billion | +23.22% |
| 2022-12-31 | CN¥1.48 Billion | +25.23% |
| 2021-12-31 | CN¥1.18 Billion | +141.56% |
| 2020-12-31 | CN¥489.78 Million | +32.85% |
| 2019-12-31 | CN¥368.68 Million | +18.82% |
| 2018-12-31 | CN¥310.29 Million | +47.25% |
| 2017-12-31 | CN¥210.73 Million | +19.56% |
| 2016-12-31 | CN¥176.26 Million | +53.99% |
| 2015-12-31 | CN¥114.46 Million | +111.59% |
| 2014-12-31 | CN¥54.10 Million | +164.46% |
| 2013-12-31 | CN¥20.46 Million | +162.19% |
| 2012-12-31 | CN¥7.80 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Anhui Huaheng Biotechnology Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 108220551991.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.08 Billion | 42.11% |
| Common Stock | CN¥249.72 Million | 9.74% |
| Other Components | CN¥1.23 Billion | 48.15% |
| Total Equity | CN¥2.56 Billion | 100.00% |
Anhui Huaheng Biotechnology Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Anhui Huaheng Biotechnology Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Elang Mahkota Teknologi Tbk
JK:EMTK
|
$759.76 Million |
|
Pursuit Attractions and Hospitality, Inc.
NYSE:PRSU
|
$759.85 Million |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771
|
$759.87 Million |
|
Theon International Plc
AS:THEON
|
$759.88 Million |
|
Shanghai Zhenhua Heavy Industries Co Ltd B
SHG:900947
|
$759.20 Million |
|
Isracard Ltd
OTCGREY:ISCDF
|
$759.18 Million |
|
Epoxy Base Electronic Material Corp Ltd
SHG:603002
|
$758.72 Million |
|
InMode Ltd
NASDAQ:INMD
|
$758.50 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Anhui Huaheng Biotechnology Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,826,971,175 to 2,564,649,586, a change of 737,678,411 (40.4%).
- Net income of 189,518,896 contributed positively to equity growth.
- Dividend payments of 183,407,679 reduced retained earnings.
- Share repurchases of 11,970,087 reduced equity.
- Other comprehensive income decreased equity by 721,619.
- Other factors increased equity by 744,258,900.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥189.52 Million | +7.39% |
| Dividends Paid | CN¥183.41 Million | -7.15% |
| Share Repurchases | CN¥11.97 Million | -0.47% |
| Other Comprehensive Income | CN¥-721.62K | -0.03% |
| Other Changes | CN¥744.26 Million | +29.02% |
| Total Change | CN¥- | 40.38% |
Book Value vs Market Value Analysis
This analysis compares Anhui Huaheng Biotechnology Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.26x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 1003.24x to 3.26x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥0.04 | CN¥36.12 | x |
| 2013-12-31 | CN¥0.08 | CN¥36.12 | x |
| 2014-12-31 | CN¥0.30 | CN¥36.12 | x |
| 2015-12-31 | CN¥0.87 | CN¥36.12 | x |
| 2016-12-31 | CN¥1.10 | CN¥36.12 | x |
| 2017-12-31 | CN¥0.93 | CN¥36.12 | x |
| 2018-12-31 | CN¥1.37 | CN¥36.12 | x |
| 2019-12-31 | CN¥1.62 | CN¥36.12 | x |
| 2020-12-31 | CN¥2.16 | CN¥36.12 | x |
| 2021-12-31 | CN¥5.23 | CN¥36.12 | x |
| 2022-12-31 | CN¥6.52 | CN¥36.12 | x |
| 2023-12-31 | CN¥8.04 | CN¥36.12 | x |
| 2024-12-31 | CN¥11.10 | CN¥36.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Anhui Huaheng Biotechnology Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.39%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.70%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 1.95x
- Recent ROE (7.39%) is below the historical average (23.98%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -48.67% | -4.38% | 0.69x | 16.14x | CN¥-4.58 Million |
| 2013 | 63.55% | 7.50% | 0.94x | 9.04x | CN¥10.95 Million |
| 2014 | 42.49% | 10.22% | 1.18x | 3.51x | CN¥17.58 Million |
| 2015 | 37.39% | 16.89% | 0.88x | 2.53x | CN¥31.35 Million |
| 2016 | 35.06% | 19.84% | 0.81x | 2.19x | CN¥44.17 Million |
| 2017 | 30.80% | 16.96% | 0.93x | 1.96x | CN¥43.82 Million |
| 2018 | 24.33% | 17.94% | 0.78x | 1.74x | CN¥44.48 Million |
| 2019 | 34.28% | 25.72% | 0.88x | 1.52x | CN¥89.51 Million |
| 2020 | 24.73% | 24.85% | 0.66x | 1.52x | CN¥72.12 Million |
| 2021 | 14.22% | 17.63% | 0.65x | 1.25x | CN¥49.92 Million |
| 2022 | 21.62% | 22.56% | 0.70x | 1.37x | CN¥171.98 Million |
| 2023 | 24.58% | 23.17% | 0.49x | 2.17x | CN¥266.36 Million |
| 2024 | 7.39% | 8.70% | 0.44x | 1.95x | CN¥-66.95 Million |
Industry Comparison
This section compares Anhui Huaheng Biotechnology Co. Ltd. A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,722,009,584
- Average return on equity (ROE) among peers: 7.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Anhui Huaheng Biotechnology Co. Ltd. A (688639) | CN¥2.67 Billion | -48.67% | 1.13x | $759.43 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $183.33 Million | -11.06% | 0.92x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $966.91 Million | 19.23% | 0.71x | $1.03 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $387.30 Million | 7.50% | 0.60x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $248.75 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.65 Billion | 1.65% | 0.84x | $860.44 Million |
| Hualan Biological EngineeringInc (002007) | $4.84 Billion | 16.95% | 0.08x | $2.01 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.20 Billion | 4.62% | 0.66x | $793.09 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $763.33 Million | 17.77% | 0.08x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $1.81 Billion | 11.12% | 0.67x | $414.37 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $3.77 Billion | 15.42% | 0.67x | $347.52 Million |